Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.

Literature DB >> 29982632

The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.

Lisa Evans DeWald¹, Julie Dyall¹, Jennifer M Sword¹, Lisa Torzewski¹, Huanying Zhou¹, Elena Postnikova¹, Erin Kollins¹, Isis Alexander¹, Robin Gross¹, Yu Cong¹, Dawn M Gerhardt¹, Reed F Johnson², Gene G Olinger¹, Michael R Holbrook¹, Lisa E Hensley¹, Peter B Jahrling^1,2.

Abstract

No therapeutics are approved for the treatment of filovirus infections. Bepridil, a calcium channel blocker developed for treating angina, was identified as a potent inhibitor of filoviruses in vitro, including Ebola and Marburg viruses, and Ebola virus in vivo. We evaluated the efficacy of bepridil in a lethal mouse model of Marburg virus disease. A dose of 12 mg/kg bepridil once or twice daily resulted in 80% or 90% survival, respectively. These data confirm bepridil's broad-spectrum anti-filovirus activity warranting further investigation of bepridil, or improved compounds with a similar mechanism, as a pan-filovirus therapeutic agent.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2018 PMID： 29982632 PMCID： PMC6249584 DOI： 10.1093/infdis/jiy332

Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226

13 in total

1. Characterization of Marburg virus glycoprotein in viral entry.

Authors: Balaji Manicassamy; Jizhen Wang; Emily Rumschlag; Stéphanie Tymen; Valentina Volchkova; Viktor Volchkov; Lijun Rong
Journal: Virology Date: 2006-09-20 Impact factor: 3.616

2. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Authors: Lisa M Johansen; Lisa Evans DeWald; Charles J Shoemaker; Benjamin G Hoffstrom; Calli M Lear-Rooney; Andrea Stossel; Elizabeth Nelson; Sue E Delos; James A Simmons; Jill M Grenier; Laura T Pierce; Hassan Pajouhesh; Joseph Lehár; Lisa E Hensley; Pamela J Glass; Judith M White; Gene G Olinger
Journal: Sci Transl Med Date: 2015-06-03 Impact factor: 17.956

3. Bepridil and amiodarone simultaneously target the Alzheimer's disease beta- and gamma-secretase via distinct mechanisms.

Authors: Stefan Mitterreiter; Richard M Page; Frits Kamp; Jessika Hopson; Edith Winkler; Huy-Riem Ha; Runa Hamid; Jochen Herms; Thomas U Mayer; Deborah J Nelson; Harald Steiner; Tobias Stahl; Ulrike Zeitschel; Steffen Rossner; Christian Haass; Stefan F Lichtenthaler
Journal: J Neurosci Date: 2010-06-30 Impact factor: 6.167

4. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.

Authors: Han Cheng; Calli M Lear-Rooney; Lisa Johansen; Elizabeth Varhegyi; Zheng W Chen; Gene G Olinger; Lijun Rong
Journal: J Virol Date: 2015-07-22 Impact factor: 5.103

5. A comparison of bepridil with amiodarone in the treatment of established atrial fibrillation.

Authors: M S Perelman; W J McKenna; E Rowland; D M Krikler
Journal: Br Heart J Date: 1987-10

Review 6. Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors: L M Hollingshead; D Faulds; A Fitton
Journal: Drugs Date: 1992-11 Impact factor: 9.546

7. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Authors: Lisa M Johansen; Jennifer M Brannan; Sue E Delos; Charles J Shoemaker; Andrea Stossel; Calli Lear; Benjamin G Hoffstrom; Lisa Evans Dewald; Kathryn L Schornberg; Corinne Scully; Joseph Lehár; Lisa E Hensley; Judith M White; Gene G Olinger
Journal: Sci Transl Med Date: 2013-06-19 Impact factor: 17.956

8. Toremifene interacts with and destabilizes the Ebola virus glycoprotein.

Authors: Yuguang Zhao; Jingshan Ren; Karl Harlos; Daniel M Jones; Antra Zeltina; Thomas A Bowden; Sergi Padilla-Parra; Elizabeth E Fry; David I Stuart
Journal: Nature Date: 2016-06-29 Impact factor: 49.962

Review 9. Discovering Drugs for the Treatment of Ebola Virus.

Authors: Sandra L Bixler; Allen J Duplantier; Sina Bavari
Journal: Curr Treat Options Infect Dis Date: 2017-08-04

10. Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.

Authors: Jingshan Ren; Yuguang Zhao; Elizabeth E Fry; David I Stuart
Journal: J Med Chem Date: 2018-01-16 Impact factor: 7.446

10 in total

Review 1. Ebola Virus Entry: From Molecular Characterization to Drug Discovery.

Authors: Cristiano Salata; Arianna Calistri; Gualtiero Alvisi; Michele Celestino; Cristina Parolin; Giorgio Palù
Journal: Viruses Date: 2019-03-19 Impact factor: 5.048

2. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension.

Authors: Lei-Ke Zhang; Yuan Sun; Haolong Zeng; Qingxing Wang; Xiaming Jiang; Wei-Juan Shang; Yan Wu; Shufen Li; Yu-Lan Zhang; Zhao-Nian Hao; Hongbo Chen; Runming Jin; Wei Liu; Hao Li; Ke Peng; Gengfu Xiao
Journal: Cell Discov Date: 2020-12-22 Impact factor: 10.849

3. Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation.

Authors: Eva Mittler; Tanwee Alkutkar; Rohit K Jangra; Kartik Chandran
Journal: mBio Date: 2021-01-12 Impact factor: 7.867

4. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.

Authors: Bruno O Villoutreix; Rajagopal Krishnamoorthy; Ryad Tamouza; Marion Leboyer; Philippe Beaune
Journal: Adv Appl Bioinform Chem Date: 2021-04-12

5. Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.

Authors: Wenyue Cao; Chia-Chuan Dean Cho; Zhi Zachary Geng; Namir Shaabani; Xinyu R Ma; Erol C Vatansever; Yugendar R Alugubelli; Yuying Ma; Sankar P Chaki; William H Ellenburg; Kai S Yang; Yuchen Qiao; Robert Allen; Benjamin W Neuman; Henry Ji; Shiqing Xu; Wenshe Ray Liu
Journal: ACS Cent Sci Date: 2022-02-02 Impact factor: 14.553

6. Treatment with Ad5-Porcine Interferon-α Attenuates Ebolavirus Disease in Pigs.

Authors: Chandrika Senthilkumaran; Andrea L Kroeker; Gregory Smith; Carissa Embury-Hyatt; Brad Collignon; Elizabeth Ramirez-Medina; Paul A Azzinaro; Bradley S Pickering; Fayna Diaz-San Segundo; Hana M Weingartl; Teresa de Los Santos
Journal: Pathogens Date: 2022-04-08

7. Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor.

Authors: Bin Wang; Jiawei Pei; Hui Zhang; Jia Li; Yamei Dang; He Liu; Yuan Wang; Liang Zhang; Libin Qi; Yuewu Yang; Linfeng Cheng; Yangchao Dong; Airong Qian; Zhikai Xu; Yingfeng Lei; Fanglin Zhang; Wei Ye
Journal: Front Pharmacol Date: 2022-08-29 Impact factor: 5.988

8. Heterogeneous network propagation with forward similarity integration to enhance drug-target association prediction.

Authors: Piyanut Tangmanussukum; Thitipong Kawichai; Apichat Suratanee; Kitiporn Plaimas
Journal: PeerJ Comput Sci Date: 2022-10-11

9. The downregulation of NCXs is positively correlated with the prognosis of stage II-IV colon cancer.

Authors: Zhixiu Xia; Changliang Wang; Hong Zhang
Journal: World J Surg Oncol Date: 2021-06-14 Impact factor: 2.754

10. Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.

Authors: Courtney L Finch; Julie Dyall; Shuang Xu; Elizabeth A Nelson; Elena Postnikova; Janie Y Liang; Huanying Zhou; Lisa Evans DeWald; Craig J Thomas; Amy Wang; Xin Xu; Emma Hughes; Patrick J Morris; Jon C Mirsalis; Linh H Nguyen; Maria P Arolfo; Bryan Koci; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling; Connie Schmaljohn; Lisa M Johansen; Gene G Olinger; Joshua T Schiffer; Judith M White
Journal: Microorganisms Date: 2021-03-10

10 in total